AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

This study is measuring levels of a hormone called AMH (anti-Mullerian hormone) in girls aged 3 to 14 with cancer, to see whether AMH can predict which children are at risk of fertility problems caused by cancer treatment such as chemotherapy, radiation, or bone marrow transplant. **You may be eligible if...** - You are a girl between 3 and 14 years old - You fall into one of three groups: (1) high risk — receiving bone marrow transplant preparation or pelvic radiation; (2) moderate/low risk — receiving chemotherapy for certain cancers (such as leukemia, neuroblastoma, Hodgkin lymphoma, or others); (3) control group — a patient with a chronic condition not receiving chemotherapy or other treatments that could harm the ovaries **You may NOT be eligible if...** - You have received or are receiving radiation to the brain or have a brain tumor - You have a current or previous ovarian disease or ovarian surgery - There is a family history of premature ovarian failure unrelated to cancer treatment - You have a serious chronic condition that affects normal growth or puberty (such as Turner syndrome, untreated severe diabetes, severe kidney problems, or cystic fibrosis) - You have a genetic condition that causes intellectual disability Talk to your doctor to see if this trial is right for you.